World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
77
Citations
35695
World Ranking
18252
National Ranking
1658

Mary O'Brien publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Mary O'Brien sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 456 publications — 50th percentile

50% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Mary O'Brien D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Mary O'Brien sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 77 D-Index — 10th percentile

10% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Mary O'Brien is affiliated with the Royal Marsden NHS Foundation Trust in the United Kingdom. Their research centers primarily around medicine, with a focus on pulmonary and respiratory medicine, oncology, and cancer research. The scope of their work extends to radiology, nuclear medicine and imaging, as well as molecular biology.

The scientist has contributed extensively to studies related to lung cancer treatments and mutations, lung cancer diagnosis and treatment, cancer immunotherapy and biomarkers, cancer genomics and diagnostics, occupational and environmental lung diseases, lung cancer research studies, and pleural and pulmonary diseases.

Mary O'Brien has authored several recent papers, including:

  • "Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial" (2022) published in The Lancet Oncology
  • "The use of telepsychiatry during COVID-19 and beyond" (2020) published in Irish Journal of Psychological Medicine

Their frequent co-authors include:

  • Sanjay Popat
  • Anna Minchom
  • Jaishree Bhosle
  • Charlotte Milner-Watts
  • Nadia Yousaf

Mary O'Brien has published in a variety of venues, most notably:

  • Lung Cancer
  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Journal of Cancer
  • Journal of Thoracic Oncology

Best Publications

  • Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

    Martin Reck;Delvys Rodríguez-Abreu;Andrew G. Robinson;Rina Hui

  • Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

    Mary E R O'Brien;N. Wigler;M. Inbar;R. Rosso

  • Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

    Martin Reck;Delvys Rodríguez-Abreu;Andrew G. Robinson;Rina Hui

  • Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

    A Webb;D Cunningham;J H Scarffe;P Harper

  • Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer

    Mary E.R. O'Brien;Tudor-Eliade Ciuleanu;Hristo Tsekov;Yaroslav Shparyk

  • Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >= 50%

    Martin Reck;Delvys Rodríguez-Abreu;Andrew G. Robinson;Rina Hui

  • Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study

    Tom Treasure;Loic Lang-Lazdunski;David Waller;Judith M Bliss

  • Do Patients With Weight Loss Have a Worse Outcome When Undergoing Chemotherapy for Lung Cancers

    P J Ross;S Ashley;A Norton;K Priest

  • Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

    Corinne Faivre-Finn;Michael Snee;Linda Ashcroft;Wiebke Appel

  • Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.

    T J Powles;T F Hickish;A Makris;S E Ashley

  • Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

    Karen Kelly;Nasser K. Altorki;Wilfried E.E. Eberhardt;Mary E.R. OBrien

  • Duration of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A Randomized Trial of Three Versus Six Courses of Mitomycin, Vinblastine, and Cisplatin

    Ian E. Smith;Mary E.R. O’Brien;Denis C. Talbot;Marianne C. Nicolson

  • Nurse led follow up and conventional medical follow up in management of patients with lung cancer: randomised trial

    Sally Moore;Jessica Corner;Jo Haviland;Mary Wells

  • Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial

    Julie R Brahmer;Delvys Rodríguez-Abreu;Andrew G Robinson;Rina Hui

  • Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer

    Joachim von Pawel;Robert Jotte;David R. Spigel;Mary E.R. O'Brien

  • Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial

    Martin F Muers;Richard J Stephens;Patricia Fisher;Liz Darlison

  • Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.

    Armando Santoro;Mary E. O'Brien;Rolf A. Stahel;Kristiaan Nackaerts

  • Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data

    Audrey Mauguen;Jean Pierre Pignon;Sarah Burdett;Caroline Domerg

  • Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy.

    P J Barrett-Lee;N P Bailey;M E R O'Brien;E Wager

  • Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report

    Anne Marie C. Dingemans;Anne Marie C. Dingemans;Lizza E.L. Hendriks;Thierry Berghmans;Antonin Levy

Frequent Co-Authors

Stanley W. Ashley
Stanley W. Ashley Brigham and Women's Hospital
Martin Reck
Martin Reck LungenClinic Grosshansdorf
David Cunningham
David Cunningham Royal Marsden NHS Foundation Trust
Johann S. de Bono
Johann S. de Bono Institute of Cancer Research
Kenneth J. O'Byrne
Kenneth J. O'Byrne Queensland University of Technology
Silvia Novello
Silvia Novello University of Turin
Paul Baas
Paul Baas Antoni van Leeuwenhoek Hospital
Julie R. Brahmer
Julie R. Brahmer Johns Hopkins University
Nir Peled
Nir Peled Hebrew University of Jerusalem
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in medicine opens doors to a wide range of healthcare careers beyond traditional medical practice. Many students are now considering related fields and advanced degrees through flexible online programs.

For those interested in hospital or clinic leadership roles, a cheapest master's in healthcare administration can be a smart option. This degree develops management skills required for high-level administrative positions in healthcare facilities.

Nurses seeking career advancement often pursue cheap dnp online programs. A Doctor of Nursing Practice (DNP) prepares graduates for leadership in clinical practice, education, or policy.

Aspiring pharmacists can explore the flexibility of pharm d online programs, earning their credentials for rewarding positions in pharmaceutical care.

Additionally, many choose non-clinical careers in data or information systems. A bachelor of health information management online prepares graduates for vital roles managing patient records and digital health infrastructure.

Online healthcare degrees offer affordability and flexibility, making it easier than ever to chart diverse and impactful career pathways in the medical field.

Best Scientists Citing Mary O'Brien

Trending Scientists

Recently Published Articles